A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+gastroesophageal (GEJ) junction or gastric (G) cancer.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Catenacci, DVT; Kim, SS; Gold, PJ; Philip, AP; Enzinger, PC; Coffie, J; Schmidt, EV; Baldwin, M; Nordstrom, JL; Bonvini, E; Wigginton, JM; Hochster, HS; Denlinger, CS; Uronis, HE; Bendell, JC; Kelly, RJ; Davidson-Moncada, JK; Lockhart, AC

Published Date

  • February 1, 2017

Published In

Volume / Issue

  • 35 / 4

Published By


  • 1

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference Location

  • Chicago, IL

Conference Start Date

  • June 2, 2017

Conference End Date

  • 2017-06-07